Cyclo Therapeutics Presents Positive Phase 3 TransportNPC™ Data in Children Under 3 Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical-stage biotechnology company focused on developing life-changing treatments for patients with rare and challenging diseases, today announced the presentation of data from…
Conference: Certis Oncology CEO Presents at 24th Annual Precision World Medicine Certis Oncology Solutions, a leader in precision oncology and translational science, recently showcased its groundbreaking advancements in artificial intelligence (AI) and machine learning (AI/ML) at the 24th Annual Precision…
Transplant of Genetically Engineered Porcine Kidney Successfully Performed in Second Patient by eGenesis eGenesis, a biotechnology firm focused on developing human-compatible engineered organs to help alleviate the global organ shortage, has announced the successful transplantation of a genetically engineered porcine…
Webinar on Ataxia-Telangiectasia Unmet Need Hosted by Quince Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company focused on advancing treatments for rare diseases, has announced that it will host an investor webinar today, Friday, February 7, 2025, at…
BlueWind Medical Announces Two-Year Durability Data for Revi® System BlueWind Medical, Ltd., a pioneer in implantable Tibial NeuroModulation (iTNM) therapies, announced today the publication of the two-year results from its pivotal OASIS study in the Journal of Urology (March 2025…
Announces Debt Exchange by Guardant Health Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, has announced a strategic move to strengthen its financial position through a debt exchange transaction. On February 6, 2025, the company entered into privately…
Agreement Secures DarioHealth’s Expansion in $1.2 Trillion Cardiometabolic Market DarioHealth Corp. (Nasdaq: DRIO) has secured a significant new agreement with a Blue Cross Blue Shield (BCBS) health plan, marking a crucial expansion in the rapidly growing digital health sector. This…
Reports Fortive Q4 and 2024 Results, Updates 2025 Outlook Fortive Corporation (NYSE: FTV) has announced its financial results for the fourth quarter and full year of 2024, highlighting strong growth across several segments and a positive outlook for 2025. The…
Nephritis in Active Lupus: Gazyva’s Superiority Proven in NEJM Dat Genentech, a member of the Roche Group, announced that a detailed analysis of its Phase III REGENCY trial of Gazyva® (obinutuzumab) in patients with active lupus nephritis (LN) has been…
Gait Disorders REEV Secures $9.2 Million to Revolutionize Mobility Assistance for Patients with Movement Disorders Gait Disorders REEV, an innovative medical technology startup specializing in intelligent, lightweight wearable robotics, has announced a significant $9.2 million funding round aimed at accelerating…
